What does jornay PM — product revenues, net mean?

This metric represents the total net revenue generated from the sale of a specific pharmaceutical product after accounting for returns, allowances, and rebates. It serves as a primary indicator of the product's market adoption and commercial success within the company's portfolio.

Collegium Pharmaceutical, Inc. (COLL) Jornay PM — Product revenues, net

Screener

Other product segments

Belbuca

$57.67M+9.6%

Xtampza ER

$45.01M—

Nucynta ER

$15.72M-21.2%

Symproic and other

$14.45M—

Nucynta IR

$14.36M-45.8%

Azstarys

$12.91M—

Symproic

$3.02M-18.9%

Nucynta ER AG

$2.78M—

Nucynta IR AG

$2.36M—

Similar metrics at other companies

VRTXProduct revenues, net — Product revenues, net

$3.33B+13.2%

VRTXOther CF product revenues — Product revenues, net

$135.9M-12.5%

VRTXOther revenues — Product revenues, net

$0-100%

VRTXALYFTREK — Product revenues, net

$573.6M+266%

VRTXCASGEVY — Product revenues, net

$76.4M+151%

VRTXJOURNAVX — Product revenues, net

$49.6M+313%

Other financials

Income statement

See full

Revenue$199.9M+6.3%

Gross profit$110.3M+1.8%

Operating income$3.7M-89.5%

Net income-$15.1M-226%

EPS (diluted)-$0.46-235%

Balance sheet

See full

Cash & equivalents$150.4M+8.8%

Total debt$5.0M-19.8%

Total equity$311.9M+34.3%

Total assets$2.1B+34.1%

Cash flow

See full

Operating cash flow$71.3M-1.5%

CapEx$496.0K+663%

Free cash flow$70.8M-2.1%

Valuation

See full

Market cap$944.15M-1.3%

Enterprise value$798.74M-3.1%

P/E19.7×-6.7×

P/S1.2×-0.2×

Profitability

See full

Gross margin60%+3.3pp

Operating margin19.5%+1.1pp

Net margin5.9%+0.8pp

FCF margin40.6%+10.8pp

Returns & leverage

See full

Return on equity17.6%+1.4pp

Debt / equity0×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:34 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-053851

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Belbuca	$57,669	$52,600	$110,318	$104,258
Xtampza ER	45,006	52,605	95,775	100,247
Jornay PM	46,058	32,626	84,951	61,165
Nucynta IR	14,356	26,501	40,434	53,918
Nucynta ER	15,723	19,946	33,957	39,632
Azstarys	12,910	—	12,910	—
Symproic	3,020	3,722	7,213	6,537
Nucynta ER AG	2,775	—	4,221	—

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s jornay PM — product revenues, net?: Collegium Pharmaceutical, Inc. (COLL) reported jornay PM — product revenues, net of $46.06M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s jornay PM — product revenues, net changed year-over-year?: Collegium Pharmaceutical, Inc.'s jornay PM — product revenues, net increased by 41.2% year-over-year, from $32.63M to $46.06M.
What does jornay PM — product revenues, net mean?: This metric represents the total net revenue generated from the sale of a specific pharmaceutical product after accounting for returns, allowances, and rebates. It serves as a primary indicator of the product's market adoption and commercial success within the company's portfolio.